Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Study Summary

To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.

Conditions

Focal Segmental Glomerulosclerosis Minimal Change Disease Immunoglobulin A Nephropathy IgA Vasculitis Alport Syndrome

Interventions / Drugs

Sparsentan Sparsentan Sparsentan

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment67 participants

Primary Completion—

Lead SponsorTravere Therapeutics, Inc.

Data Retrieved2026-04-11 04:30:13.943001+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.